Cargando…

Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis

The emergence of SARS-CoV-2 variants of concern (VOCs) and variants of interest (VOIs) with decreased susceptibility to neutralization has generated interest in assessments of booster doses and variant-specific vaccines. Clinical trial participants who received a two-dose primary series of the COVID...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choi, Angela, Koch, Matthew, Wu, Kai, Chu, Laurence, Ma, LingZhi, Hill, Anna, Nunna, Naveen, Huang, Wenmei, Oestreicher, Judy, Colpitts, Tonya, Bennett, Hamilton, Legault, Holly, Paila, Yamuna, Nestorova, Biliana, Ding, Baoyu, Montefiori, David, Pajon, Rolando, Miller, Jacqueline M., Leav, Brett, Carfi, Andrea, McPhee, Roderick, Edwards, Darin K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group US 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604720/ https://www.ncbi.nlm.nih.gov/pubmed/34526698 http://dx.doi.org/10.1038/s41591-021-01527-y

Ejemplares similares

Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial
por: Chu, Laurence, et al.
Publicado: (2022)

A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine
por: Chu, Laurence, et al.
Publicado: (2021)

Safety and Immunogenicity of a 100 μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
por: Chalkias, Spyros, et al.
Publicado: (2022)

Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants
por: Choi, Angela, et al.
Publicado: (2021)

Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial
por: Chalkias, Spyros, et al.
Publicado: (2022)

Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents
por: Ali, Kashif, et al.
Publicado: (2021)

Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice
por: Wu, Kai, et al.
Publicado: (2021)

Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial
por: Pajon, Rolando, et al.
Publicado: (2022)

Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults
por: Yassini, Patrick, et al.
Publicado: (2023)

Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial
por: El Sahly, Hana M, et al.
Publicado: (2022)

Interim statement on covid-19 vaccine booster doses
Publicado: (2021)

Interim statement on covid-19 vaccine booster doses
Publicado: (2021)

Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge
por: Baden, Lindsey R., et al.
Publicado: (2021)

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine – An Interim Analysis
por: Anderson, Evan, et al.
Publicado: (2022)

Clinical utility of Elecsys Anti-SARS-CoV-2 S assay in COVID-19 vaccination: An exploratory analysis of the mRNA-1273 phase 1 trial
por: Jochum, Simon, et al.
Publicado: (2021)

Clinical Utility of Elecsys Anti-SARS-CoV-2 S Assay in COVID-19 Vaccination: An Exploratory Analysis of the mRNA-1273 Phase 1 Trial
por: Jochum, Simon, et al.
Publicado: (2022)

Quantifying the Vaccine-Induced Humoral Immune Response to Spike-Receptor Binding Domain as a Surrogate for Neutralization Testing Following mRNA-1273 (Spikevax) Vaccination Against COVID-19
por: Kirste, Imke, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351
por: Shen, Xiaoying, et al.
Publicado: (2021)

Mastering Kali Linux for Web penetration testing: test and evaluate all aspects of the design and implementation
por: McPhee, Michael
Publicado: (2017)

The curve of binding energy: a journey into awesome and alarming world of Theodore B. Taylor
por: McPhee, John
Publicado: (1974)

Mastering Strategic Risk: A Framework for Leading and Transforming Organizations
por: McPhee, Joel
Publicado: (2014)

Withdrawn Paper: Antibacterial Effect of Five Zingiberaceae Essential Oils by Laohakunjit et al., Molecules 2007, 12, 2047-2060
por: McPhee, Derek
Publicado: (2008)

Retraction: Agarwal et al. Dynamic Action of Carotenoids in Cardioprotection and Maintenance of Cardiac Health, Molecules 2012, 17, 4755-4769
por: McPhee, Derek
Publicado: (2014)

A New Editor in Chief for Molecules (It’s Been a Fun Ride)
por: McPhee, Derek
Publicado: (2020)

THE FORMULA FOR CARDIOVASCULAR HEALTH AND WELL-BEING IN ADULTS WITH CEREBRAL PALSY
por: McPhee, Patrick
Publicado: (2022)

Living the french revolution, 1789-99 /
por: McPhee, Peter, 1948-
Publicado: (2009)

Professor Barry V.L. Potter: Winner of the 2018 Tu Youyou Award in Honor of the Co-Recipient of the 2015 Nobel Prize in Physiology or Medicine for Her Discoveries Concerning a Novel Therapy against Malaria
por: McPhee, Derek J.
Publicado: (2018)

Molecules Best Paper Award 2014
por: McPhee, Derek J.
Publicado: (2014)

Dr. Kenneth A. Jacobson: First Winner of the Tu Youyou Award, in Honor of the Co-Recipient of the 2015 Nobel Prize in Physiology or Medicine
por: McPhee, Derek J.
Publicado: (2016)

Molecules Best Paper Award 2013
por: McPhee, Derek J.
Publicado: (2013)

Corrections: “Synthesis of Sulfonamides and Evaluation of Their Histone Deacetylase (HDAC) Activity” by Jung et al., Molecules 2007, 12, 1125-1135
por: McPhee, Derek J.
Publicado: (2009)

Editorial Note: Paper by Wroczynski et al.
por: McPhee, Derek J.
Publicado: (2003)

Molecules New Aims and Scope
por: McPhee, Derek J.
Publicado: (2017)

Molecules Best Paper Award 2012
por: McPhee, Derek J.
Publicado: (2012)

Molecules after 20 Years—Looking Back and Looking Forward
por: McPhee, Derek J.
Publicado: (2015)

Molecules Best Paper Award 2015
por: McPhee, Derek J.
Publicado: (2015)

2395. An Interim Report of the Safety, Reactogenicity, and Immunogenicity of a Self-amplifying mRNA (samRNA) COVID-19 Vaccine GRT-R910 as a Booster in Healthy Adults
por: Whitaker, Jennifer, et al.
Publicado: (2023)

The Advisory Committee on Immunization Practices’ Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines — United States, 2021
por: Mbaeyi, Sarah, et al.
Publicado: (2021)

NO SAFETY CONCERNS OBSERVED WHEN THE ADJUVANTED RECOMBINANT ZOSTER VACCINE (RZV) AND THE COVID-19 MRNA-1273 BOOSTER WERE CO-ADMINISTERED IN ≥50-YEAR-OLDS
por: Naficy, A., et al.
Publicado: (2023)

Human Factor H (FH) Impairs Protective Meningococcal Anti-FHbp Antibody Responses and the Antibodies Enhance FH Binding
por: Costa, Isabella, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_1aiuhj17f9e1dr4j9v67fmkm9q